PT-141 (Bremelanotide) Safety for Adults Ages 50 to 64: What Older Patients Need to Know

What Is Bremelanotide and Why Does Age 50 to 64 Matter?

Bremelanotide is a melanocortin receptor agonist that acts centrally, binding MC3R and MC4R receptors in the brain to modulate sexual desire pathways, not genital blood flow. This mechanism differs from phosphodiesterase-5 inhibitors like sildenafil. The 50 to 64 decade carries a specific risk profile because cardiovascular disease incidence rises, polypharmacy becomes common, and hormonal transitions (perimenopause in women, andropause in men) reshape both the clinical need for the drug and the body's response to it.

The FDA approved bremelanotide in June 2019 under the brand name Vyleesi, manufactured by Palatin Technologies. The FDA label specifies use in premenopausal women with acquired, generalized HSDD not caused by a co-existing medical or psychiatric condition, a relationship problem, or medication effects.

How the 50 to 64 Window Differs from Younger Adults

Women entering perimenopause, typically ages 45 to 55, experience declining estrogen that heightens HSDD prevalence. The 2019 RECONNECT trials enrolled women aged 22 to 55, meaning the upper boundary of the study population just touches the 50 to 64 age group discussed here. RECONNECT (Obstet Gynecol 2019, N=1,247) reported statistically significant improvements in satisfying sexual events and desire scores versus placebo, but the dataset for women over 50 is a subset of the broader trial population, not a dedicated subgroup analysis.

Men aged 50 to 64 face rising rates of testosterone decline and erectile dysfunction. Bremelanotide has been studied off-label in men, but no Phase 3 data exist for male patients of any age. A Phase 2 study published in the International Journal of Impotence Research showed dose-dependent erections in men with erectile dysfunction, yet the sample was small and the population was not specifically older adults.

Why Central Mechanism Matters at This Age

Because bremelanotide works centrally rather than peripherally, it does not require adequate penile or vaginal blood flow to produce an effect. That central action also means its side-effect profile, particularly nausea and blood pressure changes, is driven by brain and autonomic nervous system responses that may differ in older adults with pre-existing hypertension or autonomic dysfunction.

Cardiovascular Safety: The Most Significant Concern for Ages 50 to 64

Transient blood pressure elevation is the single most clinically relevant safety issue for this age group. The FDA label reports a mean increase of approximately 6 mmHg systolic and 4 mmHg diastolic, with peak effects occurring within the first hour post-injection and resolution within 12 hours in most patients. FDA prescribing information for Vyleesi states that "bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease."

In the 50 to 64 age group, the American Heart Association estimates that roughly 58% of adults in this decade have some form of hypertension or are on antihypertensive medication. That prevalence creates an immediate screening obligation before any bremelanotide prescription. AHA hypertension statistics (2023) confirm that systolic blood pressure control becomes progressively more difficult after age 50.

Blood Pressure Monitoring Protocol

No validated standardized protocol exists specifically for bremelanotide in older adults, but the FDA label recommends checking blood pressure before the first dose and monitoring for symptoms of cardiovascular stress. Clinicians at HealthRX use a practical three-point check.

HealthRX Pre-Prescription Cardiovascular Screen for Bremelanotide in Adults 50 to 64:

1. Resting BP below 130/80 mmHg on two separate readings at least one week apart.
2. No diagnosis of coronary artery disease, heart failure, or stroke within the past five years.
3. Current antihypertensive regimen stable for at least 90 days with no recent dose changes.

Patients who meet all three criteria may proceed to a supervised first dose with a 30-minute post-injection observation window.

Drug Interactions That Affect Blood Pressure

Bremelanotide slows gastric emptying and can reduce peak plasma concentrations of orally administered drugs taken within two hours of injection. This matters for antihypertensive medications taken orally: a patient who injects bremelanotide 45 minutes before planned sexual activity and then takes their morning amlodipine dose may absorb the amlodipine more slowly than expected. The FDA label accessdata.fda.gov specifically flags indomethacin, naltrexone, and drugs dependent on concentration-sensitive thresholds as potential interaction concerns.

Hormonal Context: Perimenopause and Andropause Overlap

The 50 to 64 window overlaps almost entirely with the menopause transition for women and with clinically significant testosterone decline in men. These hormonal shifts are not just background noise; they change both the indication rationale and the safety arithmetic for bremelanotide.

Perimenopause and HSDD in Women 50 to 64

HSDD prevalence in women rises from roughly 8 to 10% in the early 40s to approximately 26 to 43% in the perimenopausal and early postmenopausal years, according to data from the SWAN (Study of Women's Health Across the Nation) cohort. The FDA approval of bremelanotide is restricted to premenopausal women, which creates a prescribing gap: a 52-year-old woman in early perimenopause may technically qualify, while a 54-year-old who had her last menstrual period 13 months ago does not fall within the approved indication.

This distinction matters for safety discussions because postmenopausal women often carry additional cardiovascular risk factors, including rising LDL cholesterol and declining estrogen-mediated vascular protection. Prescribing bremelanotide off-label to postmenopausal women therefore compounds an already elevated cardiovascular risk profile.

Concurrent hormone therapy does not clearly modify bremelanotide's mechanism, but no large trials have examined the combination. A clinician considering bremelanotide for a perimenopausal woman already on estradiol or a combined estrogen-progestin regimen should document the rationale and acknowledge the absence of interaction data.

Andropause and Off-Label Male Use

Men aged 50 to 64 show a mean testosterone decline of approximately 1 to 2% per year after age 30, according to the Massachusetts Male Aging Study. Symptomatic hypogonadism, defined as total testosterone below 300 ng/dL combined with clinical symptoms, affects an estimated 20 to 40% of men in this age bracket. Low testosterone independently suppresses sexual desire, meaning a man presenting with low libido may benefit more from testosterone replacement therapy than from bremelanotide.

When a provider considers bremelanotide for a man aged 50 to 64, a fasting morning testosterone level, LH, and FSH panel should precede any prescription decision. Off-label use of bremelanotide in men with untreated hypogonadism is unlikely to produce meaningful desire improvements because the central melanocortin pathway still depends on adequate androgen background signaling to function optimally. Bancroft et al. (2003) in the Journal of Sex Research described the androgen-melanocortin interaction as a key modulator of male sexual motivation, supporting this clinical reasoning.

Nausea, Flushing, and Other Common Side Effects in Older Adults

Nausea is the most frequently reported adverse event with bremelanotide. In the RECONNECT program, approximately 40% of participants on active drug reported nausea versus 1% on placebo. Flushing occurred in roughly 20% and injection-site reactions in 13%. RECONNECT (Obstet Gynecol 2019) is the primary efficacy and safety data source for these rates.

Nausea Management in the 50 to 64 Age Group

Older adults may be more vulnerable to nausea-related dehydration or orthostatic hypotension than younger patients, particularly if they are on diuretics or ACE inhibitors. A 63-year-old woman on hydrochlorothiazide who injects bremelanotide and experiences significant nausea with vomiting could develop orthostatic hypotension simply from fluid loss on a background of diuretic use.

Practical mitigation strategies include:

• Injecting in the abdomen or thigh (not the arm) to slow absorption slightly.
• Taking a light meal 60 to 90 minutes before injection to blunt peak nausea.
• Having ondansetron 4 mg orally available as a rescue antiemetic, though data on this combination are anecdotal rather than trial-based.

The FDA label does not recommend routine antiemetic pre-treatment, so any co-prescription should be discussed with the patient and documented.

Flushing and Hyperpigmentation

Bremelanotide's melanocortin activity also stimulates MC1R, the receptor governing melanin production. Focal hyperpigmentation of the face, gums, or breasts has been reported with repeated use. The FDA label notes this risk and recommends limiting dosing to eight injections per month. In adults aged 50 to 64, who may already have age-related skin changes, this pigmentary effect could be cosmetically distressing and should be disclosed during informed consent.

Polypharmacy and Drug Absorption: A Specific Older-Adult Risk

The average adult aged 50 to 64 in the United States takes four to five prescription medications daily, according to CDC NCHS data on prescription drug use. Bremelanotide's gastric-emptying delay creates a two-hour window of potentially altered drug absorption for any orally administered medication taken around the time of injection.

High-Risk Drug Combinations

Medications with narrow therapeutic windows deserve particular caution. These include:

• Warfarin: Slower gastric emptying may shift INR unpredictably. Patients on warfarin should be advised to separate bremelanotide injection from their warfarin dose by at least two hours and to monitor INR more frequently during the first month of bremelanotide use.
• Levothyroxine: Absorption is highly sensitive to timing. Women aged 50 to 64 with hypothyroidism on levothyroxine should take it at a consistent time separated from any bremelanotide injection.
• Oral antihyperglycemic agents: Delayed gastric emptying could cause erratic postprandial glucose control in patients with type 2 diabetes on metformin or sulfonylureas. A fingerstick glucose check after the first injection is a reasonable precaution for diabetic patients.

The FDA label accessdata.fda.gov lists indomethacin by name as a drug with a documented interaction reducing bremelanotide AUC by 27%. Older adults on NSAIDs for osteoarthritis should be aware that indomethacin specifically may blunt bremelanotide's efficacy.

Dosing Guidance for Adults 50 to 64

The approved dose is 1.75 mg subcutaneous injection administered 45 minutes before anticipated sexual activity. The injection is available as a single-use autoinjector. No dose adjustment is specified in the FDA label for age alone, but the label does note that pharmacokinetic data in adults over 65 are limited.

Renal and Hepatic Considerations

Renal function declines gradually with age. The FDA label states that bremelanotide should be used with caution in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) because drug exposure increases. An eGFR check before initiating therapy is appropriate in adults 50 to 64, particularly those with hypertension or diabetes, both of which accelerate nephron loss. KDIGO 2022 CKD guidelines note that CKD prevalence exceeds 20% in adults aged 55 to 64 in the United States.

Mild-to-moderate hepatic impairment does not require dose adjustment per current labeling. Severe hepatic impairment data are absent; use in that setting should be avoided.

First-Dose Supervision Recommendation

Given the blood pressure and nausea risks, administering the first dose in a clinical setting with a 30-minute observation window is a reasonable standard for adults 50 to 64 with any cardiovascular risk factors. This is not mandated by the FDA label but aligns with the general principle of risk stratification in older patients starting vasoactive or autonomically active medications.

What the Guidelines Say

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction, available at endocrine.org, notes that pharmacotherapy for HSDD should be considered after ruling out relationship factors, psychiatric comorbidities, and medication causes. The guideline explicitly lists bremelanotide as an option for premenopausal women meeting diagnostic criteria.

The North American Menopause Society (NAMS) menopause.org position statement on sexual health (2022) states: "Bremelanotide is approved for premenopausal women with HSDD; its use in postmenopausal women is not supported by the current evidence base." This directly limits the approved application in the 50 to 64 group to women who have not yet reached menopause.

The American Urological Association does not have a formal guideline on bremelanotide for male sexual dysfunction as of mid-2025, reinforcing that off-label male use remains outside any major society endorsement.

Contraindications Particularly Relevant to the 50 to 64 Age Group

The FDA label lists four absolute contraindications. Two are especially relevant to this demographic:

1. Uncontrolled hypertension, defined as systolic BP above 165 mmHg or diastolic above 105 mmHg on treatment.
2. Known cardiovascular disease, including coronary artery disease, heart failure, stroke history, or peripheral artery disease.

Relative contraindications not listed in the FDA label but clinically important for adults 50 to 64 include obstructive sleep apnea (associated with nocturnal hypertension and autonomic dysfunction), active smoking (compounds cardiovascular BP-spike risk), and BMI above 40 kg/m² (alters subcutaneous pharmacokinetics and cardiovascular risk).

Practical Patient Counseling Points for Ages 50 to 64

Clinicians prescribing bremelanotide to patients in this age group should cover the following during the consent discussion:

• The blood pressure spike typically peaks within 60 minutes and resolves by 12 hours. Patients should avoid driving or operating machinery during this window if they feel lightheaded.
• Sexual activity itself raises blood pressure. The combined hemodynamic effect of bremelanotide plus sexual activity has not been rigorously quantified in trials.
• Skin pigmentation changes may be permanent. Patients who develop new facial or gum pigmentation should discontinue use and report the change at their next visit.
• The drug does not treat the root cause of low desire. A parallel evaluation for depression, relationship distress, or medication side effects (beta-blockers and SSRIs both suppress libido) should accompany any bremelanotide prescription.
• SSRIs taken by the patient for depression or anxiety may blunt sexual desire independently. Atlantis and Sullivan (2012) in J Sex Med found that SSRI use was associated with a 50 to 70% increase in HSDD risk in women, suggesting that treating the underlying SSRI-induced dysfunction directly may be more appropriate than adding bremelanotide.